
SILK Stock Forecast & Price Target
SILK Analyst Ratings
Bulls say
Silk Road Medical Inc. has exhibited strong growth in its TCAR procedure volumes, achieving an annual growth rate of approximately 20% in early 2024, indicating a solid demand for its innovative treatment for carotid artery disease. The introduction of tapered stents and a new carotid National Coverage Determination (NCD) has contributed to a positive outlook, with vascular surgeons reporting increased carotid referral volumes and an overall improvement in category awareness. Additionally, the company's financial performance demonstrates year-over-year leverage improvement, as well as expectations for continued robust growth reflected in higher revenue forecasts and a favorable market valuation multiple recovery.
Bears say
Silk Road Medical has faced a significant decline in stock performance, with shares dropping 74% year-to-date, raising concerns among investors. The company has lowered its full-year 2023 revenue guidance from $180-184 million to $170-174 million, reflecting a disappointing execution despite initial promise in TCAR volume growth. Additionally, a combination of factors, including a choppy operational landscape and uncertainties surrounding CMS's decision to reopen the carotid National Coverage Determination, has contributed to a negative outlook for the company's financial future.
This aggregate rating is based on analysts' research of Silk Road Medical Inc and is not a guaranteed prediction by Public.com or investment advice.
SILK Analyst Forecast & Price Prediction
Start investing in SILK
Order type
Buy in
Order amount
Est. shares
0 shares